MIP Technologies and FeF Chemicals sign Research and Development Agreement
MIP Technologies AB, a developer of molecular molecularly imprinted polymers for separations and drug discovery, announced that it has signed a research and development agreement with FeF Chemicals, a subsidiary of Novo Nordisk. During this program of work, MIP Technologies will develop for FeF a novel separation material with the potential for use in large scale protein purification. Under the terms of the Agreement, MIP Technologies will receive R&D funding including milestone payments, while FeF/Novo Nordisk will receive a license for manufacturing and use of the new material. MIP Technologies will retain the rights to use this new material in all fields with the exception of applications in diabetes.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.